A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The primary purpose of this multi-centre, double blind-study is to evaluate the clinical response of patients with moderate to severe Cohn\'s Disease (CD) following treatment with different doses and dose regimens of Olokizumab, relative to placebo.
Epistemonikos ID: 3a3358460af43884b93dd6e6899f23993b52413f
First added on: May 11, 2024